- Home
- QTTB vs FTHM Comparison
QTTB vs FTHM Comparison
Compare QTTB & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- FTHM
- Stock Information
- Founded
- QTTB 2015
- FTHM 2010
- Country
- QTTB United States
- FTHM United States
- Employees
- QTTB N/A
- FTHM N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- FTHM Real Estate
- Sector
- QTTB Health Care
- FTHM Finance
- Exchange
- QTTB Nasdaq
- FTHM Nasdaq
- Market Cap
- QTTB 19.0M
- FTHM 33.6M
- IPO Year
- QTTB N/A
- FTHM 2020
- Fundamental
- Price
- QTTB $1.50
- FTHM $1.24
- Analyst Decision
- QTTB Hold
- FTHM Buy
- Analyst Count
- QTTB 8
- FTHM 1
- Target Price
- QTTB $24.00
- FTHM $2.50
- AVG Volume (30 Days)
- QTTB 142.2K
- FTHM 79.7K
- Earning Date
- QTTB 08-07-2025
- FTHM 08-11-2025
- Dividend Yield
- QTTB N/A
- FTHM N/A
- EPS Growth
- QTTB N/A
- FTHM N/A
- EPS
- QTTB N/A
- FTHM N/A
- Revenue
- QTTB N/A
- FTHM $357,816,000.00
- Revenue This Year
- QTTB N/A
- FTHM $32.40
- Revenue Next Year
- QTTB N/A
- FTHM $18.04
- P/E Ratio
- QTTB N/A
- FTHM N/A
- Revenue Growth
- QTTB N/A
- FTHM 5.80
- 52 Week Low
- QTTB $1.38
- FTHM $0.65
- 52 Week High
- QTTB $53.79
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- QTTB 40.47
- FTHM 58.94
- Support Level
- QTTB $1.47
- FTHM $1.24
- Resistance Level
- QTTB $1.65
- FTHM $1.36
- Average True Range (ATR)
- QTTB 0.12
- FTHM 0.08
- MACD
- QTTB -0.02
- FTHM -0.01
- Stochastic Oscillator
- QTTB 15.69
- FTHM 70.73
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.